National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 1 of 2003)

Overview

The National Health Act 1953 was enacted to provide a framework for the administration of health services in Australia, including the regulation of drugs and medicinal preparations under the Pharmaceutical Benefits Scheme (PBS). This legislation was introduced to address the need for a systematic approach to the provision of healthcare services, ensuring that essential medications were accessible and affordable for all Australians. The Act is overseen by the Australian Parliament and aims to maintain a sustainable and efficient healthcare system. The policy objective is to ensure that the PBS provides access to necessary medications while controlling costs and maintaining quality. The Pharmaceutical Benefits Declaration under subsection 85 (2AA) serves to update the list of substances covered under the PBS, ensuring that the scheme remains relevant and effective in meeting the healthcare needs of the population.

Scope and Application

The Pharmaceutical Benefits Declaration under subsection 85 (2AA) of the National Health Act 1953 applies to the cessation of certain drugs and medicinal preparations from the coverage of Part VII of the Act. The Act operates at the Commonwealth level and applies to the specified drugs and medicinal preparations listed in the Schedule of the Declaration. These drugs and medicinal preparations, namely Carbomer 940, Dextran 40 with Glucose, Dextran 40 with Sodium Chloride, Dextran 70 with Sodium Chloride, Fosfestrol Sodium, and Methylphenobarbitone, will no longer be subject to the provisions of Part VII of the National Health Act 1953. The Declaration is made by the Acting Assistant Secretary, Pharmaceutical Benefits Branch, Department of Health and Ageing, and is effective from 1 February 2003. The scope of the Declaration is limited to the drugs and medicinal preparations listed in the Schedule, and there are no stated exclusions or exemptions within the text of the Declaration itself. The application of the Act may be further extended or restricted through subordinate instruments, which are not detailed in the provided text.

Key Provisions

The main operative sections of this legislative instrument are sections 2 and the Schedule (section 2). Section 2 of the Declaration specifies that certain drugs and medicinal preparations will cease to be covered under Part VII of the National Health Act 1953, which pertains to the Pharmaceutical Benefits Scheme (PBS). This means that these specified items will no longer be eligible for subsidies under the PBS. The Schedule lists the specific drugs and preparations affected by this cessation, including Carbomer 940, Dextran 40 with Glucose, Dextran 40 with Sodium Chloride, Dextran 70 with Sodium Chloride, Fosfestrol Sodium, and Methylphenobarbitone. The obligations and requirements imposed by this Act are primarily administrative and procedural. The Acting Assistant Secretary, Pharmaceutical Benefits Branch, Department of Health and Ageing, in this case Andrew Searle Mitchell, must obtain the advice of the Pharmaceutical Benefits Advisory Committee before making such a declaration (subsection 85(2AB)). This ensures that the decision to remove these drugs from the PBS is based on expert advice and consideration of the clinical and economic implications. The declaration itself must be dated and signed by the appropriate official, as demonstrated in the text. Offences, penalties, or consequences for breaches of the Act are not explicitly detailed within the text provided. However, in the context of the National Health Act 1953, any misuse or improper administration of the PBS could potentially lead to civil or criminal penalties. For instance, fraudulent claims or misrepresentations could result in fines or imprisonment, depending on the severity of the offence. The precise penalties would be governed by other sections of the National Health Act 1953 and associated regulations. This legislative instrument focuses on the formal process of updating the PBS list rather than the enforcement mechanisms for non-compliance with the PBS regulations.